PQA follows a systematic, transparent and consensus-based development process to ensure that measures are important, scientifically acceptable, feasible and usable. This approach produces strong, consistent results, but it also takes time.
PQA has published the 2022 PQA Measure Manual and Value Sets. The PQA Measure Manual includes detailed narrative specifications for PQA measures, which are needed to implement the measures accurately and appropriately. PQA Value Sets, which include National Drug Codes (NDCs), are required to calculate PQA measures as specified.
The Pharmacy Quality Alliance (PQA) seeks interested pharmacy and payer partners to participate in proof-of-concept pilots to implement high priority blood pressure and hemoglobin A1c measure concepts in value-based payment arrangements (VBAs).
Prescription opioid-related deaths are one of the leading preventable public health problems. High-risk prescribing practices have contributed to the opioid overdose epidemic. These include overlapping opioid and benzodiazepine prescriptions, prescribing high-dose opioids and using multiple prescribers or pharmacies for opioid prescriptions.
Concepts Could Be Used in Payer-Pharmacy Value-Based Arrangements
PQA follows a systematic, transparent and consensus-based development process to ensure that measures are important, scientifically acceptable, feasible and usable. This approach produces strong, consistent results, but it also takes time.
This fall and into 2022, there are numerous opportunities for PQA members to participate in our measure development process. As a consensus-based and member-driven organization, this is the moment for you and your organization to inform and influence decisions on measures across the development and stewardship continuum. Here's what's coming up soon. Information on each of these will be emailed to members as we get closer to the opportunity.
PQA endorsed two new diabetes-focused health plan performance measures in December 2020. More than 34 million Americans have diabetes, according to the Centers for Disease Control and Prevention. These measures will help evaluate the quality of care for a disease that annually costs America $327 billion.
